Corcept Therapeutics (CORT) financials
Corcept Therapeutics revenue and earnings by year
Corcept Therapeutics's revenue was $761 million in the fiscal year to December 31, 2025, up 12.8% from the year before. Net income was $98.2 million, 12.9% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 28.2% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 761 | 675 | 482 | 402 | 366 | 354 | 306 | 251 | 159 | 81 |
| Revenue growth | 12.8% | 39.9% | 20.0% | 9.8% | 3.4% | 15.5% | 22.0% | 57.8% | 95.8% | — |
| Gross profit | 748 | 664 | 476 | 396 | 361 | 348 | 301 | 246 | 156 | 79 |
| Gross margin | 98.3% | 98.4% | 98.7% | 98.7% | 98.6% | 98.4% | 98.2% | 97.9% | 97.8% | 97.5% |
| Operating income | 45 | 137 | 107 | 113 | 124 | 128 | 112 | 89 | 53 | 10 |
| Operating margin | 5.9% | 20.3% | 22.2% | 28.0% | 34.0% | 36.2% | 36.4% | 35.6% | 33.2% | 12.5% |
| Net income | 98 | 140 | 105 | 101 | 113 | 106 | 94 | 75 | 129 | 8 |
| Net margin | 12.9% | 20.7% | 21.9% | 25.2% | 30.7% | 30.0% | 30.7% | 30.0% | 81.1% | 10.0% |
| Diluted EPS | $0.82 | $1.23 | $0.94 | $0.87 | $0.89 | $0.85 | $0.78 | $0.60 | $1.02 | $0.07 |
| Free cash flow | 142 | 196 | 127 | 120 | 167 | 151 | 135 | 115 | 61 | 18 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open CORT in Markets.
How Corcept Therapeutics makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Hypercortisolism Products | $209M | 81.4% |
| Lifyorli | $47.6M | 18.6% |
See also: CORT valuation and P/E history · CORT returns
No forecast, no recommendation. This page describes Corcept Therapeutics from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.